EMAS position statement: Testosterone replacement therapy in the aging male‏.

Dimopoulou, Christina; Ceausu, Iuliana; Depypere, Herman; Lambrinoudaki, Irene; Mueck, Alfred; Pérez-López, Faustino R; Rees, Margaret; van der Schouw, Yvonne T; Senturk, Levent M; Simonsini, Tommaso; Stevenson, John C; Stute, Petra; Goulis, Dimitrios G (2016). EMAS position statement: Testosterone replacement therapy in the aging male‏. Maturitas, 84, pp. 94-99. Elsevier 10.1016/j.maturitas.2015.11.003

[img] Text
1-s2.0-S0378512215008087-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (855kB) | Request a copy

INTRODUCTION Late-onset hypogonadism (LOH) represents a common clinical entity in aging males, characterized by the presence of symptoms (most usually of a sexual nature, such as decreased libido, decreased spontaneous erections and erectile dysfunction) and signs, in combination with low serum testosterone concentrations. Whether testosterone replacement therapy (TRT) should be offered to those individuals is still under extensive debate. AIMS The aim of this position statement is to provide and critically appraise evidence on TRT in the aging male, focusing on pathophysiology and characteristics of LOH, indications for TRT, available therapeutic agents, monitoring and treatment-associated risks. MATERIALS AND METHODS Literature review and consensus of expert opinion. RESULTS AND CONCLUSIONS Diagnosis and treatment of LOH is justified, if a combination of symptoms of testosterone deficiency and low testosterone is present. Patients receiving TRT could profit with regard to obesity, metabolic syndrome, type 2 diabetes mellitus, sexual function and osteoporosis and should undergo scheduled testing for adverse events regularly. Potential adverse effects of TRT on cardiovascular disease, prostate cancer and sleep apnea are as yet unclear and remain to be investigated in large-scale prospective studies. Management of aging men with LOH should include individual evaluation of co-morbidities and careful risk versus benefit assessment.

Item Type:

Journal Article (Review Article)


04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Gynaecology

UniBE Contributor:

Stute, Petra


600 Technology > 610 Medicine & health








Monika Zehr

Date Deposited:

20 Apr 2016 10:26

Last Modified:

15 Sep 2017 16:27

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

Aging male, Late-onset hypogonadism, Testosterone replacement





Actions (login required)

Edit item Edit item
Provide Feedback